4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole CHEMBL778 DEXMEDETOMIDINE MPV 1440 BDBM50085683 (+)-4-((S)-alpha,2,3-trimethylbenzyl)imidazole
BDBM50241196 Dexmedetomidine CHEMBL397901 (R)-5-(1-(2,3-dimethylphenyl)ethyl)-1H-imidazole 4-[(R)-1-(2,3-Dimethyl-phenyl)-ethyl]-1H-imidazole
- Millan, MJ; Dekeyne, A; Newman-Tancredi, A; Cussac, D; Audinot, V; Milligan, G; Duqueyroix, D; Girardon, S; Mullot, J; Boutin, JA; Nicolas, JP; Renouard-Try, A; Lacoste, JM; Cordi, A S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther 295: 1192-205 (2000)
- Alpha2-Adrenergic Receptor Binding Assay The membrane preparation was prepared as described by Newman-Tancredi, A.; Nicolas, J,-P.; Audinot, V.; Gavaudan, S.; Verriele, L.; Touzard, M.; Chaput, C.; Richard, N.; Millan, N. J. (Action of alpha2 Adrenoreceptor Ligands at alpha2A and 5-HT1A Receptors: the Antagonist, Atipamezole, and the Agonist, Dexmedetomidine, are Highly Selective for alpha2A Adrenoreceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 1998, 358, 197-206). These membranes (30 ug proteins/ml for CHO-halpha2A and CHO-halpha2B, 100 ug protein/ml for CHO-halpha2C) were incubated for 60 min at ambient temperature in binding buffer (33 mM Tris-HCl, 1 mM EDTA, pH 7.5) in a final volume of 500 uL containing 0.8 or 1 or 2 nM [3H]RX821002 respectively for the adrenergic receptors halpha2A, halpha2B and halpha2C. Incubation was halted by rapid vacuum filtration through GF/C glass fibre filters followed by three successive washings in ice-cold binding buffer. Non-specific binding was determined using 10 uM phentolamine.